You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
The most commonly reported adverse reactions (≥10%) in the Gamifant® (emapalumab-lzsg) pivotal trial included:
|Adverse reactions||Gamifant (N=34)||Adverse reactions||Gamifant (N=34)|
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3-6
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.1
Download the Start Form now or contact Gamifant Patient Services at 833-597-6530.